IL10 and neoplasm: We evaluated a panel of basal cytokines more commonly involved in the tumor control and progression (IL-1 beta, IL-6, IL-8, IL-10, IL-12, TNF-α) both in 144 healthy donors and in 55 patients affected by MRCC treated with IL-2 based regimens.